Back to Screener

AgomAb Therapeutics NV American Depositary Shares (AGMB)

Price$9.92
Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (4W)0.63%
VGM Score48.76
Market Capitalization$670.17M

All Metrics

Indicated Dividend (Annual)$0.00
Price vs S&P 500 (YTD)-28.46%
EPS (TTM)$-1.48
10-Day Avg Trading Volume0.06M
EPS Excl Extra (TTM)$-1.48
EPS (Annual)$-1.48
ROI (Annual)-47.33%
Cash / Share (Quarterly)$0.00
ROA (Last FY)-40.69%
EBITD / Share (TTM)$-1.40
Cash Flow / Share (Annual)$-0.00
P/B Ratio3.84x
Net Income / Employee (Annual)$-1,166,670
Net Interest Coverage (TTM)-17.59x
EPS Incl Extra (Annual)$-1.48
Current Ratio (Annual)6.52x
Quick Ratio (Quarterly)6.52x
3-Month Avg Trading Volume0.17M
Revenue / Employee (TTM)$0
52-Week High$17.45
EPS Excl Extra (Annual)$-1.48
Quick Ratio (Annual)6.52x
13-Week Price Return-19.01%
Total Debt / Equity (Annual)0.01x
Current Ratio (Quarterly)6.52x
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.00
3-Month Return Std Dev79.82%
Net Income / Employee (TTM)$-1,166,670
ROE (Last FY)-47.78%
EPS Basic Excl Extra (Annual)$-1.48
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$-1.48
Revenue / Share (Annual)$0.00
Year-to-Date Return-18.84%
5-Day Price Return5.69%
EPS Normalized (Annual)$-1.48
Month-to-Date Return5.69%
EBITD / Share (Annual)$-1.40
LT Debt / Equity (Annual)0.00x
EPS Basic Excl Extra (TTM)$-1.48
Price vs S&P 500 (13W)-29.51%
Beta1.89x
Revenue / Share (TTM)$0.00
52-Week Low$9.00
mGradeC
vgmGradeC
Show chart for

Analyst Recommendations

Apr 2026
May 2026
Jun 2026
4.30
4.30
4.30

Industry Peers — Biological Products(178)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
AGMBAgomAb Therapeutics NV American Depositary Shares
C$9.92
AMGNAmgen IncCCC$349.58
GILDGilead Sciences IncCBC$129.16
ARGXargenx SE American Depositary SharesDAB$891.32
RVMDRevolution Medicines, Inc. Common StockFA$149.23
BIIBBiogen Inc. Common StockBDB$195.34
BNTXBioNTech SE American Depositary ShareCCD$88.08
MRNAModerna, Inc. Common StockCBB$47.44
NBIXNeurocrine Biosciences IncCBB$163.88
EXELExelixis IncCBB$52.70
KRYSKrystal Biotech, Inc. Common StockDBA$301.00

About

AgomAb Therapeutics is a clinical-stage biopharmaceutical company developing small molecule and antibody therapies for chronic fibrotic diseases and related immunological disorders with significant unmet medical needs. The company's pipeline targets established inflammatory pathways using validated modalities, with lead candidates Ontunisertib (AGMB-129) and AGMB-447. AgomAb's approach aims to overcome limitations of existing treatment options for fibrotic indications.